Comparative cardioprotective effects and mechanisms of vitamin E and lisinopril against ischemic reperfusion induced cardiac toxicity

The present study was undertaken to scientifically evaluate, validate and compare the cardioprotective effects of lisinopril (Lsp), an angiotensin converting enzyme (ACE) inhibitor and vitamin E (Vit E), an antioxidant in the setting of ischemia and reperfusion (I–R) injury. An open chest left anterior descending coronary artery occlusion and reperfusion induced myocardial injury cardiotoxicity model was used in the present study. Hemodynamic, biochemical and histopathological assessment of myocardial injury was undertaken. Pre-treatment (1 month) with Lsp (50 mg/kg) and Vit E (100 mg/kg) to healthy experimental controls did not adversely affect the histopathological architecture of the myocardium as well as the baseline antioxidant parameters. Subsequent to I–R injury, Lsp demonstrated modest antioxidant effects, superior recovery in left ventricular function as compared to the control IR group. Histopathological and biochemical assessment of injury confirmed the myocardial salvaging effect of this intervention. The cardioprotection afforded by Lsp was found to be superior as compared to Vit E treatment.

► The cardioprotective potential of lisinopril (Lsp) and vitamin E (Vit E) has been well elucidated by the dosing protocol of the present study.
► Myocardial savaging effects of Lsp and Vit E may be attributed to antioxidant activity and favorable restoration of ventricular dynamics
► Preserved myocardial CPK activity and histopathologic evaluation further confirm the cardioprotective potential of Lsp and Vit E.
► The data of the current study provide evidence that the beneficial effects of Lsp was superior to those exerted by Vit E.